MADISON, N.J., Dec. 29, 2010 /PRNewswire-FirstCall/ — Pfizer
Animal Health today announced an agreement to acquire Synbiotics
Corporation (Pink Sheets:
SYNB), a privately held, Kansas City-based leader in the
development, manufacture and marketing of immunodiagnostic tests
for companion and food production animals.
(Logo:
http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)
Veterinary immunodiagnostics, a methodology using
antigen-antibody reaction to detect viruses or bacteria in animals,
is a sector growing an estimated 8% annually, twice the rate of the
animal health industry as a whole. The global
immunodiagnostics market is valued at $735 million, according to
industry sources. Factors accelerating growth include
increasing interest among companion animal owners in monitoring the
health and maintaining wellness of their dogs, cats and horses.
Likewise, livestock producers, striving to meet increasing
worldwide demand for animal-derived food protein, are placing
greater emphasis on immunodiagnostics to safeguard the health of
livestock animals.
“Our acquisition of Synbiotics, with its best-in-class product
portfolio, promising research and development pipeline, and
manufacturing capability, will bring Pfizer Animal Health closer to
its goal of becoming a comprehensive solutions provider to the
animal health industry,” said Juan Ramon Alaix, president, Pfizer
Animal Health. “By integrating animal health diagnostics with
our innovative portfolio of vaccines and medicines, we can do more
to help veterinarians deliver optimal care for livestock and
companion animals and provide the right medicine to the right
animal at the right time.”
According to Mr. Alaix, the acquisition will not only allow
Pfizer Animal Health to enhance its offerings to veterinarians at
point of care in the clinic and on
‘/>”/>
SOURCE